ArticleF1000Research2025
Personalized Care in the UAE : A Study on Precision Medicine Awareness and Accessibility among the general population.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precision medicine is an emerging approach that tailors treatments based on an individual's genetic profile. The UAE has made significant strides in this field through initiatives like the National Genomics Strategy and the Emirati Genome Program. However, public awareness and engagement remain key challenges. Purpose: This study assesses awareness, acceptance, and utilization of precision medicine among UAE residents. Methods: A cross-sectional online survey was conducted using a snowball sampling method. The survey collected demographic data, health status, knowledge, and experiences with precision medicine. Descriptive statistics and chi-square tests were used to analyze associations. Results: Most participants (94.3%) were under 50 years old, 62.5% were female, and 60.0% held a bachelor's degree. Awareness of precision medicine was moderate (55.3%), with higher familiarity among females and students. While 40% believed its main benefit was optimizing drug effectiveness, 38.5% viewed it as crucial for preventing adverse drug reactions. Family and friends (29.5%) were the primary sources of information, yet 25.5% had never heard of precision medicine. Awareness of insurance coverage was low, with 59.0% uncertain about their policy. Genetic testing participation was associated with education level (p < 0.05). Acceptance of precision medicine was higher among individuals with chronic illnesses (p = 0.004). Familiarity scores varied significantly by occupation (p < 0.001) and income (p = 0.004), with higher-income individuals showing greater awareness. Males had a broader range of practice scores (p = 0.003), and individuals with chronic conditions were more aware of precision medicine (p = 0.023). Conclusion: Despite advancements, public engagement with precision medicine remains limited. Targeted educational initiatives, improved accessibility, and increased awareness of insurance coverage may enhance adoption and utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.